For decades, aspirin was viewed as a medical marvel in a bottle. Its role in secondary prevention—preventing recurrent heart attacks and strokes—has always been clear and lifesaving. But its use in primary prevention, aimed at preventing a first cardiovascular event in otherwise healthy adults, became one of the longest and most contentious debates in modern medicine.

After years of conflicting studies and shifting guidelines, a clear multidisciplinary consensus has finally emerged. For most adults without established cardiovascular disease, routine aspirin use for primary prevention now causes more harm than benefit. This conclusion reflects the unified judgment of cardiology, gastroenterology, and neurology—an uncommon but decisive alignment in preventive medicine.

The Early Appeal of Aspirin for Primary Prevention

Aspirin’s rise in primary prevention followed its dramatic success in secondary prevention. The landmark Physicians’ Health Study in 1989 reported a 44% reduction in first myocardial infarction among male physicians taking aspirin every other day. Combined with aspirin’s low cost and accessibility, enthusiasm spread rapidly throughout the 1990s.

Guidelines soon followed. Earlier USPSTF recommendations supported aspirin use in select middle-aged adults when cardiovascular benefits were believed to outweigh bleeding risks. Lower “baby aspirin” doses (75–100 mg) became standard after studies demonstrated effective platelet inhibition with reduced gastrointestinal toxicity.

Bleeding Risk, Mortality Neutrality, and the Cancer Question

As aspirin use expanded, so did recognition of its risks. By irreversibly inhibiting cyclooxygenase-1, aspirin compromises gastric mucosal protection and increases bleeding risk. The 2009 Antithrombotic Trialists’ Collaboration meta-analysis clarified the trade-off: modest reductions in nonfatal cardiovascular events were offset by comparable increases in major gastrointestinal and extracranial bleeding, with no reduction in all-cause mortality.

Hopes briefly shifted toward cancer prevention, particularly colorectal cancer. Observational data suggested long-term aspirin use might reduce cancer incidence. However, later randomized evidence and USPSTF reassessment concluded that potential cancer benefits were insufficient to justify routine aspirin therapy, especially given the certainty of bleeding harm.

Modern Trials End the Debate

Between 2018 and 2021, three contemporary randomized controlled trials definitively reshaped aspirin’s role in primary prevention. ARRIVE found no cardiovascular benefit in moderate-risk adults. ASCEND showed that in patients with diabetes, reductions in vascular events were nearly canceled out by increased major bleeding. ASPREE delivered the most striking result—no benefit in healthy adults over 70, with increased bleeding and higher all-cause mortality.

These findings reflect modern medicine’s success elsewhere. Better blood pressure control, statin therapy, smoking cessation, and lifestyle interventions have reduced baseline cardiovascular risk. Aspirin’s bleeding risk, however, remains unchanged.

The Final Verdict from Guidelines

The 2022 USPSTF recommendation formalized this shift. Aspirin received a “C” grade for adults aged 40–59 with elevated cardiovascular risk, meaning decisions should be individualized. For adults 60 and older, aspirin earned a “D” grade, with clear evidence that harms outweigh benefits.

Modern cardiovascular prevention now prioritizes statins for cholesterol management, aggressive blood pressure control, diabetes care, diet, physical activity, and targeted supplements when evidence supports their use. Aspirin remains essential for secondary prevention—but its era as a routine preventive tool is over.

References

ASPREE Trial – National Library of Medicine
ARRIVE Trial – The Lancet
ASCEND Trial – American College of Cardiology
USPSTF 2022 Aspirin Recommendation
Antithrombotic Trialists’ Collaboration Meta-analysis